Online citations, reference lists, and bibliographies.
← Back to Search

Impact Of Tumour Thickness On Survival After Radical Radiation And Surgery In Malignant Pleural Mesothelioma

M. D. de Perrot, Z. Dong, P. Bradbury, D. Patsios, Shaf Keshavjee, N. Leighl, A. Hope, R. Feld, J. Cho
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Tumour thickness was assessed to determine if this parameter could refine patients' selection for multimodality therapy in malignant pleural mesothelioma. We reviewed 65 consecutive treatment-naïve malignant pleural mesothelioma patients undergoing surgery for mesothelioma after radiation therapy (SMART). Total tumour thickness was determined by measuring the maximal thickness on nine predefined sectors on the chest wall, mediastinum and diaphragm. After a median follow-up of 19 months, 40 patients (62%) developed recurrence and 36 died (55%). Total tumour thickness, ranging between 2.4 and 21 cm (median 6.9 cm), correlated with tumour volume (p<0.0001, R2=0.29) and maximum standardised uptake value (p=0.006, R2=0.11). Total tumour thickness had a significant impact on overall survival and disease-free survival in univariate analysis. In multivariate analysis, total tumour thickness remained an independent predictor of survival (p=0.02, hazard ratio (HR) 1.12, 95% CI 1.02–1.23) and disease-free survival (p=0.01, HR 1.13, 95% CI 1.03–1.24) along with epithelial histologic subtype (p<0.0001, HR 0.25, 95% CI 0.13–0.50) and pN2 disease (p=0.03, HR 2.15, 95% CI 1.07–4.33). Diaphragmatic tumour thickness correlated best with time to recurrence (p=0.002, R2=0.22) and time to death (p=0.003, R2=0.2). The impact of tumour thickness on survival and disease-free survival independent of histologic subtypes and nodal disease is extremely encouraging. This parameter could potentially be used to refine the clinical staging of malignant pleural mesothelioma and optimise patient selection for radical treatment. Tumour thickness is an independent predictor of outcome after radical treatment for malignant pleural mesothelioma http://ow.ly/KCbT306wDBN
This paper references
10.1097/JTO.0000000000000211
Observer Variability in Mesothelioma Tumor Thickness Measurements: Defining Minimally Measurable Lesions
S. Armato (2014)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1016/J.CRAD.2006.09.030
Benefits of routine use of coronal and sagittal reformations in multi-slice CT examination of the abdomen and pelvis ☆
K. Sandrasegaran (2007)
10.1200/JCO.2008.20.3943
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1093/ejcts/ezw074
Impact of induction therapy on postoperative outcome after extrapleural pneumonectomy for malignant pleural mesothelioma: does induction-accelerated hemithoracic radiation increase the surgical risk?
P. Mordant (2016)
10.1200/JCO.2005.07.050
Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials.
D. Fennell (2005)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1016/j.jtcvs.2015.09.129
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
M. D. de Perrot (2016)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1097/01.rli.0000248972.06586.9b
Routine Isotropic Computed Tomography Scanning of Chest: Value of Coronal and Sagittal Reformations
J. Rydberg (2007)
10.2214/AJR.11.7015
Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume.
R. Gill (2012)
10.1097/JTO.0000000000000661
A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years’ Experience
I. Opitz (2015)
10.1016/J.LUNGCAN.2005.03.007
The role of PET in the surgical management of malignant pleural mesothelioma.
R. Flores (2005)
10.1097/RCT.0000000000000174
Use of Computed Tomography and Positron Emission Tomography/Computed Tomography for Staging of Local Extent in Patients With Malignant Pleural Mesothelioma
T. Frauenfelder (2015)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1097/JTO.0000000000000078
A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy: The “SMART” Approach for Resectable Malignant Pleural Mesothelioma
B. Cho (2014)
10.1183/09031936.00039510
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial
P. V. Van Schil (2010)
10.1007/s00259-013-2561-1
The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma
A. Klabatsa (2013)
Pathology and genetics of tumours of the lung , pleura, thymus and heart
W. D. Travis (2004)
10.1016/j.jtho.2016.09.121
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
D. Rice (2016)
10.1183/09031936.00207213
Multimodal management of malignant pleural mesothelioma: where are we today?
P. V. Van Schil (2014)
10.1016/j.jtho.2016.08.147
The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma
A. Nowak (2016)
10.1016/j.clinimag.2007.06.006
Benefits of routine use of coronal and sagittal reformations in multi-slice CT examination of the abdomen and pelvis.
K. Sandrasegaran (2007)
10.3978/j.issn.2225-319X.2012.11.10
Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database.
V. Rusch (2012)



This paper is referenced by
10.1016/j.jtho.2018.04.034
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
S. Armato (2018)
10.21037/jtd.2018.01.171
Treatment of malignant pleural mesothelioma: lessons learned and quo vadis?
S. Boeluekbas (2018)
10.1080/17476348.2019.1607300
The timing of chemotherapy in the management plan for medically operable early-stage malignant pleural mesothelioma
K. Shohdy (2019)
10.1016/j.jtcvs.2019.10.122
Prognostic influence of tumor microenvironment after hypofractionated radiation and surgery for mesothelioma.
M. D. de Perrot (2019)
10.1183/13993003.00319-2017
Malignant pleural mesothelioma: new treatments, new hopes?
A. Scherpereel (2017)
10.21037/tlcr.2017.06.03
Radio-immunotherapy and chemo-immunotherapy as a novel treatment paradigm in malignant pleural mesothelioma.
Licun Wu (2017)
10.1007/978-3-030-16884-1_10
Measuring Malignant Pleural Mesothelioma
A. Nowak (2019)
10.21037/SHC.2018.09.02
What are the implications of the revised N staging system for surgery
H. Batırel (2018)
10.1016/j.jtho.2018.02.021
Progress in the Management of Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1016/J.CLLC.2019.06.019
The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma.
C. Proto (2019)
10.1016/S1470-2045(17)30459-X
Radiotherapy for the treatment of malignant pleural mesothelioma.
M. Perrot (2017)
10.1016/j.jtho.2018.02.021
State of the Art : Advances in Malignant Pleural Mesothelioma in 2017
Amanda J McCambridge (2018)
10.1016/j.jtcvs.2018.10.005
A thinner peel to peel: Pleural thickness is prognostic in mesothelioma.
Shawn S. Groth (2019)
10.1016/j.jtcvs.2018.09.106
Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma
M. Hashimoto (2019)
10.3322/caac.21572
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
M. Carbone (2019)
10.21037/jtd.2018.01.23
Staging in the era of international databases: documented improvements with remaining challenges.
R. Cameron (2018)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
J. Willmann (2019)
10.1016/j.jtho.2019.08.012
Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Mesothelioma Applied Research Foundation Clinical T
R. Gill (2019)
10.1016/j.lungcan.2018.01.001
Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival.
Juuso Paajanen (2018)
10.1007/s10147-020-01780-0
Clinicopathological features of radiological early malignant pleural mesothelioma with no apparent tumor or pleural thickening
Akifumi Nakamura (2020)
10.1093/jnci/djx175
Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma
R. Gill (2018)
10.1016/j.jtho.2019.08.2506
EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach.
A. Nicholson (2019)
10.21037/tlcr-19-488
Does size matter? -a population-based analysis of malignant pleural mesothelioma.
J. He (2020)
10.3390/ijms21176306
Repurposing Quinacrine for Treatment of Malignant Mesothelioma: In-Vitro Therapeutic and Mechanistic Evaluation
N. Kulkarni (2020)
Semantic Scholar Logo Some data provided by SemanticScholar